

Alipharma Limited

Annual Report and Unaudited Financial Statements
for the Year Ended 31 March 2019

The Moffatts Partnership LLP
Progress House
396 Wilmslow Road
Withington
Manchester
M20 3BN

Alipharma Limited

Contents

Company Information	<u>1</u>
Balance Sheet	<u>2</u> to <u>3</u>
Notes to the Financial Statements	<u>4</u> to <u>9</u>

Alipharma Limited

Company Information

Director Mr MA Ali

Company secretary Mrs. S Ali

Registered office 287B Stretford Road
Urmston
Manchester
Lancashire
M41 9NU

Accountants The Moffatts Partnership LLP
Progress House
396 Wilmslow Road
Withington
Manchester
M20 3BN

Alipharma Limited
(Registration number: 06091428)
Balance Sheet as at 31 March 2019

	Note	2019 £	2018 £
Fixed assets			
Intangible assets	<u>4</u>	60,000	70,000
Tangible assets	<u>5</u>	114,745	36,091
		<u>174,745</u>	<u>106,091</u>
Current assets			
Stocks	<u>6</u>	69,391	68,725
Debtors	<u>7</u>	1,480,633	1,210,022
Cash at bank and in hand		73,567	162,845
		1,623,591	1,441,592
Creditors: Amounts falling due within one year	<u>8</u>	(534,450)	(441,637)
Net current assets		<u>1,089,141</u>	<u>999,955</u>
Total assets less current liabilities		1,263,886	1,106,046
Provisions for liabilities		<u>(21,802)</u>	<u>(4,404)</u>
Net assets		<u>1,242,084</u>	<u>1,101,642</u>
Capital and reserves			
Called up share capital	<u>9</u>	100	100
Profit and loss account		1,241,984	1,101,542
Total equity		<u>1,242,084</u>	<u>1,101,642</u>

For the financial year ending 31 March 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

The notes on pages 4 to 9 form an integral part of these financial statements.

Alipharma Limited

(Registration number: 06091428)
Balance Sheet as at 31 March 2019

Approved and authorised by the director on 20 December 2019

.....

Mr MA Ali
Director

The notes on pages 4 to 9 form an integral part of these financial statements.
Page 3

Alipharma Limited

Notes to the Financial Statements for the Year Ended 31 March 2019

1 General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:

287B Stretford Road

Urmston

Manchester

Lancashire

M41 9NU

These financial statements were authorised for issue by the director on 20 December 2019.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company's activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:

The amount of revenue can be reliably measured;

it is probable that future economic benefits will flow to the entity;

and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Alipharma Limited

Notes to the Financial Statements for the Year Ended 31 March 2019

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Fixtures & Fittings	15% Reducing balance basis
Motor Vehicles	25% Reducing balance basis
Land & Buildings	10% Straight line basis
Office Equipment	33% Reducing balance basis

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company's interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class	Amortisation method and rate
Goodwill	10% Straight line basis

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Alipharma Limited

Notes to the Financial Statements for the Year Ended 31 March 2019

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company's shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 Staff numbers

The average number of persons employed by the company (including the director) during the year, was 15 (2018 - 14).

Alipharma Limited

Notes to the Financial Statements for the Year Ended 31 March 2019

4 Intangible assets

	Goodwill £	Total £
Cost or valuation		
At 1 April 2018	100,000	100,000
At 31 March 2019	100,000	100,000
Amortisation		
At 1 April 2018	30,000	30,000
Amortisation charge	10,000	10,000
At 31 March 2019	40,000	40,000
Carrying amount		
At 31 March 2019	60,000	60,000
At 31 March 2018	70,000	70,000

The aggregate amount of research and development expenditure recognised as an expense during the period is £Nil (2018 - £Nil).

5 Tangible assets

	Land and buildings £	Furniture, fittings and equipment £	Motor vehicles £	Total £
Cost or valuation				
At 1 April 2018	10,974	78,045	29,522	118,541
Additions	-	58	106,700	106,758
At 31 March 2019	10,974	78,103	136,222	225,299
Depreciation				
At 1 April 2018	1,097	55,843	25,511	82,451
Charge for the year	1,098	3,773	23,232	28,103
At 31 March 2019	2,195	59,616	48,743	110,554
Carrying amount				
At 31 March 2019	8,779	18,487	87,479	114,745
At 31 March 2018	9,877	22,203	4,011	36,091

Included within the net book value of land and buildings above is £8,779 (2018 - £9,877) in respect of freehold land and buildings.

Alipharma Limited

Notes to the Financial Statements for the Year Ended 31 March 2019

6 Stocks

	2019 £	2018 £
Other inventories	<u>69,391</u>	<u>68,725</u>

7 Debtors

	2019 £	2018 £
Trade debtors	382,312	372,925
Prepayments	6,627	11,515
Other debtors	<u>1,091,694</u>	<u>825,582</u>
	<u>1,480,633</u>	<u>1,210,022</u>

Alipharma Limited

Notes to the Financial Statements for the Year Ended 31 March 2019

8 Creditors

Creditors: amounts falling due within one year

	2019 £	2018 £
Due within one year		
Trade creditors	249,844	231,797
Taxation and social security	6,951	3,552
Accruals and deferred income	141,069	148,185
Other creditors	136,586	58,103
	<u>534,450</u>	<u>441,637</u>

9 Share capital

Allotted, called up and fully paid shares

	2019		2018	
	No.	£	No.	£
Ordinary share class 1 of £1 each	100	100	100	100

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.